title: A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
abstract: We investigated a recent (January 1999 to December 2009) cohort of 95 elderly Hodgkin lymphoma subjects. At diagnosis, median age was 67 years (range, 60-89 years), whereas 61% had significant comorbidity, 26% were unfit, 17% had a geriatric syndrome, and 13% had loss of activities of daily living. Overall response rate to therapy was 85%, whereas incidence of bleomycin lung toxicity was 32% (with associated mortality rate, 25%). With 66-month median follow-up, 2-year and 5-year overall survival were 73% and 58%, respectively (advanced-stage, 63% and 46%, respectively). Most International Prognostic Score factors were not prognostic on univariate analyses, whereas Cox multivariate regression identified 2 risk factors associated with inferior overall survival: (1) age more than 70 years (2.24; 95% CI, 1.16-4.33, P = .02) and (2) loss of activities of daily living (2.71; 95% CI, 1.07-6.84, P = .04). Furthermore, a novel survival model based on number of these risk factors (0, 1, or 2) showed differential 2-year OS of 83%, 70%, and 13%, respectively (P < .0001) and 5-year OS of 73%, 51%, and 0%, respectively (P < .0001).
authors: Division of Hematology/Oncology, University of Massachusetts Medical School, Worcester, 01655, USA. andrew.evens@umassmed.edu
authors: Andrew M
authors: AM
authors: Evens
authors: Irene
authors: I
authors: Helenowski
authors: Erika
authors: E
authors: Ramsdale
authors: Chadi
authors: C
authors: Nabhan
authors: Reem
authors: R
authors: Karmali
authors: Britt
authors: B
authors: Hanson
authors: Benjamin
authors: B
authors: Parsons
authors: Scott
authors: S
authors: Smith
authors: Annette
authors: A
authors: Larsen
authors: June M
authors: JM
authors: McKoy
authors: Borko
authors: B
authors: Jovanovic
authors: Stephanie
authors: S
authors: Gregory
authors: Leo I
authors: LI
authors: Gordon
authors: Sonali M
authors: SM
authors: Smith
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate